Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.
How this was made
The 30-second read
Why it matters
The FDA approval is a discrete regulatory milestone based on the REPLENISH Phase III trial, highlighting sustained remission and steroid-sparing outcomes, which can translate into incremental revenue expectations and improved product lifecycle durability.
Market read
Traders can treat this as a fresh, company-specific regulatory catalyst that may re-rate Cosentyx’s growth outlook via label expansion in a steroid-dependent disease area.
What to watch
The article notes increased hypersensitivity reactions and infections versus placebo, plus rare serious/fatal events, which could temper uptake and influence post-approval monitoring sentiment.
Background
Cosentyx (secukinumab) is an established anti-IL-17A biologic with multiple approved immune-mediated indications; this FDA action adds a new adult PMR indication.
Ticker impact
Novartis announced FDA approval of Cosentyx (secukinumab) 150 mg for polymyalgia rheumatica, its first anti-IL-17 biologic for this indication.
Likely upward bias as the market prices in label expansion and potential uptake beyond steroid-dependent care.
The article is a direct FDA approval news item for Novartis’ marketed product, with pivotal Phase III efficacy and steroid-sparing claims and a clear new US indication.
Market effects
Reinforces anti-IL-17 positioning in inflammatory rheumatology and may increase competitive pressure on steroid-centric PMR treatment approaches.
US label expansion can drive near-term sentiment for global immunology peers with rheumatology pipelines, though this article is US-specific.
Adds to the global regulatory momentum for Cosentyx, with EU already approved and Japan reviews ongoing, supporting broader international uptake expectations.
Counterpoint
FDA approval does not guarantee rapid PMR uptake; real-world prescribing may be constrained by payer coverage, clinician inertia, and safety/tolerability perceptions.
Key entities
- companyNovartis
Company announcing FDA approval of Cosentyx for polymyalgia rheumatica (PMR).
- drugCosentyx (secukinumab)
Anti-IL-17A biologic receiving FDA approval for PMR 150 mg in adults with inadequate response or intolerance to corticosteroids.
- regulatorFDA
Regulatory body approving Cosentyx for the PMR indication.
- clinical_trialREPLENISH trial
Phase III study supporting the approval, including sustained remission and steroid tapering results.




